Shikiar Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Shikiar Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,500	Closed	-$251K	–	78
2023 Q4	$251K	Buy	+3,500	New	+$201K	0.08%	65
2023 Q3	–	Sell	-3,500	Closed	-$222K	–	81
2023 Q2	$222K	Buy	+3,500	New	+$218K	0.07%	72
2022 Q2	–	Sell	-3,500	Closed	-$214K	–	99
2022 Q1	$214K	Buy	+3,500	New	+$182K	0.06%	90

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Shikiar Asset Management's ITCI Position: Q1 2024 in Review

Shikiar Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 3,500 shares — an estimated $251K sold.

Shikiar Asset Management first reported a position in ITCI in Q1 2022 and held it in 3 quarters. The position peaked at $251K in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

Shikiar Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
Shikiar Asset Management sold 3,500 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $251K.
Shikiar Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 3 quarters.
Shikiar Asset Management's Intra-Cellular Therapies Inc. position peaked at $251K in Q4 2023.
346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Shikiar Asset Management's 13F filing for Q1 2024, filed 22 Apr 2024.